Elevated levels of activin A in clinical and experimental pulmonary hypertension

1 Research Institute for Internal Medicine, Rikshospitalet University Hospital, 2 Institute for Experimental Medical Research, Ullevål University Hospital, 3 Department of Pulmonary Medicine, Ullevål University Hospital, 4 Center for Heart Failure Research, 5 Institute for Surgical Research, Rikshos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of applied physiology (1985) 2009-04, Vol.106 (4), p.1356-1364
Hauptverfasser: Yndestad, Arne, Larsen, Karl-Otto, Oie, Erik, Ueland, Thor, Smith, Camilla, Halvorsen, Bente, Sjaastad, Ivar, Skjonsberg, Ole Henning, Pedersen, Turid M, Anfinsen, Ole-Gunnar, Damas, Jan Kristian, Christensen, Geir, Aukrust, Pal, Andreassen, Arne K
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:1 Research Institute for Internal Medicine, Rikshospitalet University Hospital, 2 Institute for Experimental Medical Research, Ullevål University Hospital, 3 Department of Pulmonary Medicine, Ullevål University Hospital, 4 Center for Heart Failure Research, 5 Institute for Surgical Research, Rikshospitalet University Hospital, 6 Medical Department, Diakonhjemmet Hospital, 7 Department of Endocrinology, Rikshospitalet University Hospital, 8 Department of Cardiology, Ullevål University Hospital, 9 Department of Cardiology, and 10 Section of Clinical Immunology and Infectious Diseases, Rikshospitalet University Hospital, University of Oslo, Oslo, Norway Submitted 4 June 2008 ; accepted in final form 2 February 2009 Activin A, a member of the transforming growth factor (TGF)-β superfamily, is involved in regulation of tissue remodeling and inflammation. Herein, we wanted to explore a role for activin A in pulmonary hypertension (PH). Circulating levels of activin A and its binding protein follistatin were measured in patients with PH ( n = 47) and control subjects ( n = 14). To investigate synthesis and localization of pulmonary activin A, we utilized an experimental model of hypoxia-induced PH. In mouse lungs, we also explored signaling pathways that can be activated by activin A, such as phosphorylation of Smads, which are mediators of TGF-β signaling. Possible pathophysiological mechanisms initiated by activin A were explored by exposing pulmonary arterial smooth muscle cells in culture to this cytokine. Elevated levels of activin A and follistatin were found in patients with PH, and activin A levels were significantly related to mortality. Immunohistochemistry of lung autopsies from PH patients and lungs with experimental PH localized activin A primarily to alveolar macrophages and bronchial epithelial cells. Mice with PH exhibited increased pulmonary levels of mRNA for activin A and follistatin in the lungs, and also elevated pulmonary levels of phosphorylated Smad2. Finally, we found that activin A increased proliferation and induced gene expression of endothelin-1 and plasminogen activator inhibitor-1 in pulmonary artery smooth muscle cells, mediators that could contribute to vascular remodeling. Our findings in both clinical and experimental studies suggest a role for activin A in the development of various types of PH. growth factors; inflammation; pathogenesis Address for reprint requests and other correspondence: A. Yndestad, Research Institute for
ISSN:8750-7587
1522-1601
DOI:10.1152/japplphysiol.90719.2008